Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 14/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2716408 | 0.93 | CAPN1 (0.69) | CAPN1CNR1CNR2 | |
| SCHEMBL2716990 | 0.93 | CAPN1 (0.58) | CAPN1SLC6A9CNR2 | |
| SCHEMBL2714449 | 0.92 | CAPN1 (0.59) | CAPN1CXCR2CNR1CNR2 | |
| SCHEMBL2714668 | 0.91 | CAPN1 (0.58) | CAPN1CXCR2 | |
| SCHEMBL2714806 | 0.90 | CAPN1 (0.57) | CAPN1SLC6A9CXCR2 | |
| SCHEMBL2715228 | 0.90 | CAPN1 (0.56) | CAPN1 | |
| SCHEMBL2715422 | 0.89 | CAPN1 (0.54) | CAPN1SLC6A9CNR1CNR2 | |
| SCHEMBL2714909 | 0.87 | CAPN1 (0.60) | CAPN1 | |
| SCHEMBL2716294 | 0.86 | CAPN1 (0.53) | CAPN1MAP4K4SLC6A9CNR1CNR2 | |
| SCHEMBL540969 | 0.82 | CAPN1 (0.87) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238130-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2012-05-02 | — | — | EP | claimed |
| US-9150553-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-06 | — | — | US | disclosed |
| EP-2238130-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2012-05-02 | — | — | EP | disclosed |
| US-20110059968-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-03-10 | — | — | US | disclosed |
| EP-2238130-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | Abbott GmbH & Co. KG (DE) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009083581-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059968-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN2, CAPN1, CAPNS1 | CAPN1 2/4885MAP4K4 3442/4885SLC6A9 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.